img

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2024

A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
According to Mr Accuracy reports’s new survey, global Monoclonal antibodies (mAbs) Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monoclonal antibodies (mAbs) Biosimilars market research.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Monoclonal antibodies (mAbs) Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others

Segment by Application


Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monoclonal antibodies (mAbs) Biosimilars report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2024-2034)
2.2 Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Region
2.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Region (2024-2024)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2024-2034)
2.3 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
2.3.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
2.3.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
2.3.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
2.3.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2024-2024)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2024-2024)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
3.5 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2024-2024)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2024-2034)
5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2024-2024)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2024)
8.4 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024)
9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024)
10.4 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biocon
11.1.1 Biocon Company Detail
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.1.5 Biocon Recent Development
11.2 Celltrion
11.2.1 Celltrion Company Detail
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.2.5 Celltrion Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Detail
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.3.5 Dr. Reddy's Laboratories Recent Development
11.4 Hospira
11.4.1 Hospira Company Detail
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.4.5 Hospira Recent Development
11.5 3SBio
11.5.1 3SBio Company Detail
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.5.5 3SBio Recent Development
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Detail
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.6.5 Accord Healthcare Recent Development
11.7 AET Biotech
11.7.1 AET Biotech Company Detail
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.7.5 AET Biotech Recent Development
11.8 Allergan
11.8.1 Allergan Company Detail
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.8.5 Allergan Recent Development
11.9 Amega Biotech
11.9.1 Amega Biotech Company Detail
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
11.9.5 Amega Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Erythropoietin (EPO)
Table 3. Key Players of Human Growth Hormone (HGH)
Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 5. Key Players of Monoclonal Antibody (mAb)
Table 6. Key Players of Insulin
Table 7. Key Players of Interferon (IFN)
Table 8. Key Players of Others
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2024) & (US$ Million)
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2024)
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2034)
Table 15. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 16. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 17. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 18. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 19. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2024-2024) & (US$ Million)
Table 20. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2024-2024)
Table 21. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Table 22. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2022
Table 23. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2024-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 26. Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2024-2024) & (US$ Million)
Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2024)
Table 30. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 31. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Table 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2024-2024) & (US$ Million)
Table 33. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2024)
Table 34. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 35. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 37. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 38. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 39. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 40. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 41. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 42. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 43. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2024) & (US$ Million)
Table 44. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2034) & (US$ Million)
Table 45. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 46. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 47. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 48. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 49. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 50. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 51. Biocon Company Detail
Table 52. Biocon Business Overview
Table 53. Biocon Monoclonal antibodies (mAbs) Biosimilars Product
Table 54. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 55. Biocon Recent Development
Table 56. Celltrion Company Detail
Table 57. Celltrion Business Overview
Table 58. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product
Table 59. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 60. Celltrion Recent Development
Table 61. Dr. Reddy's Laboratories Company Detail
Table 62. Dr. Reddy's Laboratories Business Overview
Table 63. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product
Table 64. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 65. Dr. Reddy's Laboratories Recent Development
Table 66. Hospira Company Detail
Table 67. Hospira Business Overview
Table 68. Hospira Monoclonal antibodies (mAbs) Biosimilars Product
Table 69. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 70. Hospira Recent Development
Table 71. 3SBio Company Detail
Table 72. 3SBio Business Overview
Table 73. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product
Table 74. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 75. 3SBio Recent Development
Table 76. Accord Healthcare Company Detail
Table 77. Accord Healthcare Business Overview
Table 78. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product
Table 79. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 80. Accord Healthcare Recent Development
Table 81. AET Biotech Company Detail
Table 82. AET Biotech Business Overview
Table 83. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 84. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 85. AET Biotech Recent Development
Table 86. Allergan Company Detail
Table 87. Allergan Business Overview
Table 88. Allergan Monoclonal antibodies (mAbs) Biosimilars Product
Table 89. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 90. Allergan Recent Development
Table 91. Amega Biotech Company Detail
Table 92. Amega Biotech Business Overview
Table 93. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 94. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024) & (US$ Million)
Table 95. Amega Biotech Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2022 VS 2034
Figure 3. Erythropoietin (EPO) Features
Figure 4. Human Growth Hormone (HGH) Features
Figure 5. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 6. Monoclonal Antibody (mAb) Features
Figure 7. Insulin Features
Figure 8. Interferon (IFN) Features
Figure 9. Others Features
Figure 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2022 VS 2034
Figure 12. Anti-Cancer Case Studies
Figure 13. Anti-Inflammatory/Autoimmune Case Studies
Figure 14. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region: 2022 VS 2034
Figure 18. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2022
Figure 19. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
Figure 21. North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 23. United States Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 24. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 27. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. France Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Nordic Countries Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2034)
Figure 35. China Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. India Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 43. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 44. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 46. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 47. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 48. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 49. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 50. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 51. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 52. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 53. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 54. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 55. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 56. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 57. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2024-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed